Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | CDC7 | O00311 | 2/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21595010 | 0.83 | HDAC1 (0.57) | HDAC1HDAC8HDAC6GAATDP1 | |
| SCHEMBL21601974 | 0.82 | HDAC1 (0.51) | HDAC1HDAC8HDAC6RAB9AGAA | |
| SCHEMBL2080725 | 0.81 | RAB9A (0.68) | HDAC1HDAC8HDAC6RAB9AGAA | |
| SCHEMBL4806945 | 0.80 | MEN1 (0.52) | HDAC1HDAC8HDAC6RAB9AGAA | |
| SCHEMBL4806955 | 0.80 | MEN1 (0.52) | HDAC1HDAC8HDAC6RAB9AGAA | |
| SCHEMBL22807240 | 0.78 | MAPT (0.41) | RAB9AGAATDP1ALDH1A1NPC1 | |
| SCHEMBL5753728 | 0.77 | HDAC1 (0.55) | HDAC1HDAC8HDAC6RAB9AGAA | |
| SCHEMBL21595120 | 0.76 | RAB9A (0.47) | RAB9AGAATDP1ALDH1A1NPC1 | |
| SCHEMBL17742732 | 0.74 | HDAC1 (0.60) | HDAC1HDAC8HDAC6GAATDP1 | |
| SCHEMBL14564380 | 0.73 | RAB9A (0.58) | HDAC1HDAC8HDAC6RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-04-25 | — | — | US | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | HDAC1 3062/4885HDAC8 1942/4885HDAC6 1711/4885 |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | HDAC1 3062/4885HDAC8 1942/4885HDAC6 1711/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | HDAC1 3062/4885HDAC8 1942/4885HDAC6 1711/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | HDAC1 3062/4885HDAC8 1942/4885HDAC6 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.